As new therapeutics are emerging for the treatment of patients with HCV, the nomenclature for defining virologic response is becoming outdated, leading to inconsistencies and confusion. A recent paper has attempted to devise a new nomenclature that will be able to respond to future advances in HCV therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
European Association of the Study of the Liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 32 (Suppl. 1), 2–8 (2012).
McHutchison, J. G. et al. Peginterferon α-2b or α-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361, 580–593 (2009).
Mallet, V. et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Int. Med. 149, 399–403 (2008).
McHutchison, J. G. et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292–1303 (2010).
Zeuzem, S. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417–2428 (2011).
Bacon, B. R. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207–1217 (2011).
Jacobson, I. M. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364, 2405–2416 (2011).
Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216–224 (2012).
Gane, E. J. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467–1475 (2010).
Wedemeyer, H. et al. Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. Hepatology http://dx.doi.org/10.1002/hep.25888.
Acknowledgements
The author would like to thank Dr Matthew Albert for his help in the discussion of the manuscript.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
S. Pol has been a speaker and received grant/research support from BMS, Gilead, Roche and MSD. He has been a consultant and speaker for Janssen-Tibotec. S. Pol has been a speaker for Boehringer Ingelheim, Sanofi, Novartis and Vertex.
Rights and permissions
About this article
Cite this article
Pol, S. HCV virologic response—new nomenclature recommendations. Nat Rev Gastroenterol Hepatol 9, 619–620 (2012). https://doi.org/10.1038/nrgastro.2012.164
Published:
Issue date:
DOI: https://doi.org/10.1038/nrgastro.2012.164
